Objective： To observe the effect of Lishukang capsules on inflammatory response and oxidative stress in patients with maintenance hemodialysis(MHD). Methods：A total of 140 cases of MHD patients were selected and divided into the control group and the observation group according to the random number table method，with 70 cases in each group. The control group was given routine symptomatic treatment， and the observation group was additionally treated with Lishukang capsules based on the treatment of the control group. Both groups were treated for six months. The clinical effects and the incidences of complications in the two groups were compared. Before and after treatment， Chinese medicine syndrome score and the levels of interleukin-6(IL-6)，tumor necrosis factor-α(TNF-α)，C-reactive protein(CRP)， malonaldehyde(MDA)，homocysteine(Hcy) and superoxide dismutase(SOD) in the two groups were compared. Results：The total effective rate was 88.57% in the observation group， higher than that of 75.71% in the control group(P＜0.05). The incidence of complications was 30.00% in the observation group，lower than that of 48.57% in the control group(P＜0.05). After treatment，Chinese medicine syndrome scores and the levels of IL-6，TNF-α，CRP，MDA and Hcy in the two groups were decreased when compared with those before treatment(P＜0.05)，and SOD levels were increased(P＜0.05)；Chinese medicine syndrome score and the levels of IL- 6，TNF- α，CRP，MDA and Hcy in the observation group were lower than those in the control group(P＜0.05)，and SOD level was higher(P＜0.05). Conclusion：Lishukang capsules for MHD patients can improve the clinical effect，effectively relieve the clinical symptoms of patients and the inflammatory responses，regulate the oxidative stress state，and reduce the incidence of complications.